In a dynamic move set to galvanize the Japanese pharmaceutical sector, Astellas Pharma Inc. and Mitsubishi Research Institute (MRI) have announced a strategic alliance aimed at fostering the growth of pharmaceutical startups in Japan. This partnership is a testament to the shared commitment of both organizations to harness their collective expertise and resources to cultivate a new generation of globally competitive drug-discovery ventures.
The partnership comes as a response to the Ministry of Health, Labour and Welfare’s Medical Innovation Support Office (MEDISO) initiative, which seeks to address the insufficient practical application of Japan’s advanced life sciences technologies. MRI, which has been entrusted to operate MEDISO since 2018, has been instrumental in aiding budding drug-discovery startups commercialize their intellectual property.
Hirofumi Suzuki, Executive Officer and General Manager of the Public Innovation Unit at MRI, highlighted the essential role of external expertise in the successful commercialization of drug discoveries. He expressed optimism that the partnership would expedite this process by connecting startups with globally active pharmaceutical companies from the onset.
Under this innovative agreement, MRI will leverage its extensive track record of supporting over twelve hundred startup and academic ventures through MEDISO to design bespoke support programs for the participants. Astellas Pharma, on the other hand, will provide drug-discovery startups participating in the acceleration program with access to its state-of-the-art laboratory and office space at SakuLab-Tsukuba, situated within the Astellas Tsukuba Research Center.
This strategic location at SakuLab-Tsukuba offers more than just physical resources. Startups will have the unique opportunity to benefit from expert consultations with Astellas’ seasoned professionals and foster valuable connections with fellow residents and researchers. This collaborative environment is expected to accelerate their drug discovery research, bolstering their global competitiveness.
Tadaaki Taniguchi, M.D., Ph.D., Chief Research & Development Officer (CRDO) of Astellas Pharma, expressed his pleasure at the agreement with MRI. Reiterating Astellas Pharma’s dedication to nurturing innovative ideas and technologies, Taniguchi emphasized that the memorandum of understanding would bolster and expedite drug discovery research by Japanese startups. This, he believes, will ultimately culminate in the creation of innovative medical solutions.
The partnership between Astellas Pharma and MRI marks a significant step forward in strengthening Japan’s position as a global hub for drug discovery. By providing the necessary resources, expertise, and networking opportunities, this alliance is poised to ignite a new wave of pharmaceutical innovation in Japan, propelling the nation’s drug-discovery startups onto the global stage. This collaboration serves as a model for how established organizations can effectively support the growth of emerging companies, fueling the future of the biotechnology industry.
Read more from finanznachrichten.de
